BG-12 (Tecfidera)
I keep track of what’s on the horizon as far as MS research is concerned. Given it takes many years for products to come to fruition with all the studies that need to be done in order to be considered for FDA approval, something that looks good in the beginning can fall flat somewhere along the route. BG-12, now known as Tecfidera, had my interest in its infancy as a drug.

I was so impressed with the data that it was the one drug I had even considered a substitute therapy—to finally leave Betaseron and the injections behind seemed a real possibility. read more